Formulation and specifications: Injection: 100mg (10ml)/bottle, 500mg (50ml)/bottle
Indications:
1. Follicular non-Hodgkin’s lymphoma with indications for treatment.
2. CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL).
3.Single agent for maintenance therapy in patients with follicular lymphoma (FL) after complete or partial remission with rituximab in combination with chemotherapy.
4. In combination with fludarabine and cyclophosphamide (FC) for the treatment of primary relapsed/refractory chronic lymphocytic leukemia.
Key points for rational drug use:
1. The most common adverse reaction after receiving rituximab therapy is an infusion-related reaction, which occurs primarily with the first infusion. Symptoms may include nausea, pruritus, fever, rubella/rash, chills, chills, sneezing, angioneurotic edema, throat irritation, cough, and bronchospasm with or without hypotension or hypertension associated with drug therapy. Each rituximab drip should be preceded by an anti-allergy medication. Glucocorticoids should also be premedicated if the treatment regimen used does not include glucocorticoids.
2. Cases of hepatitis B reactivation have been reported in patients receiving chemotherapy with rituximab and cell proliferation inhibiting drugs. All patients should be screened for hepatitis B virus according to local guidelines, including at least hepatitis B surface antigen and hepatitis B core antibody markers, prior to initiation of rituximab therapy. Patients with active hepatitis B should not be treated with rituximab.
3. Rituximab is contraindicated in patients with severe active infection or severely impaired immune response (e.g., hypoglobulinemia, severely decreased CD4 or CD8 cell counts) and in patients with severe heart failure [New York Heart Association (NYHA) Class IV]; rituximab in combination with methotrexate is contraindicated during pregnancy.
4. Rituximab should be administered in strict compliance with the dosage instructions, with particular attention to the control of the starting titration rate.
5. Closely monitor patients for cytokine release syndrome and tumor lysis syndrome.
6. Patients with preexisting pulmonary insufficiency or tumor pulmonary infiltration must undergo chest imaging.
7. Patients treated with rituximab should not be vaccinated with live viral vaccines; they may receive non-live vaccines, but the response rate to non-live vaccines may be decreased.